AR and neoplasm: In exploratory analyses of efficacy in subgroups defined by AR-expression level (percentage of tumor cells with nuclear expression) and by HR status (HR + or HR−), CBR24 was similar in all subgroups versus the overall patient population (see Online Resource 6: Table S3).